Testing FLQ-101 safety in premature babies
Part of Eyes & vision, Genetic & congenital clinical trials.
This study tests a new medicine called FLQ-101 in very premature babies born between 25 and 27 weeks of pregnancy. The goal is to see if the medicine is safe and how it works in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby must be born between 25 weeks and 0 days and 27 weeks and 6 days of pregnancy.
- Parent or legal guardian must give written permission for the baby to join.
- Your baby must not have certain eye problems, serious birth defects, or heart disease.
- Your baby must not have severe bleeding in the brain (grade 2, 3, or 4).
- Your baby must not have a birth weight below the 10th percentile for their age and sex.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the tiny blood vessels in the back of the eye (retina) of premature infants who are at risk for retinopathy of prematurity, a condition that can harm vision. It aims to improve care and monitoring by using advanced eye imaging to see more detail than current methods.
This study looks at children who had ROP (an eye problem in premature babies) to see how their vision and the back of the eye (retina) develop over time. It compares children who received treatment with those who did not, to learn more about long-term effects.
This study tests a new eye imaging device to check for retinopathy of prematurity (ROP), a condition that can affect vision in premature babies. It may help doctors diagnose ROP earlier and more easily at the bedside.
This trial tests whether a low dose of conbercept, given as an eye injection, can safely treat type 1 ROP (an eye disease in premature babies). The goal is to stop abnormal blood vessel growth and prevent vision loss.
This study looks at the long-term eye health of people who were born prematurely and screened for a condition called retinopathy of prematurity (ROP), which affects the blood vessels in the eye. It aims to understand how their vision has developed over time.
This study looks at how red blood cell transfusions affect health problems in babies born before 32 weeks of pregnancy. It may help doctors understand if transfusions are linked to complications of prematurity.
Hear when a new Retinopathy of Prematurity (ROP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.